Navigation Links
Regeneron Ranked by Science Magazine as the #2 Employer in the Global Biopharmaceutical Industry
Date:9/15/2011

TARRYTOWN, N.Y., Sept. 15, 2011 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced that Science magazine has ranked Regeneron as the #2 employer in the global biopharmaceutical industry in its annual survey of Top Employers.

"It is extremely satisfying for Regeneron to be recognized by Science as one of the best  places to be a scientist," said Leonard S. Schleifer, M.D., Ph.D., President and Chief Executive Officer of Regeneron.  "It is a priority at Regeneron to create an environment where talented individuals can conduct groundbreaking science and where creativity and innovation are encouraged and recognized.  We are grateful to Science for acknowledging our science-based culture and to our fantastic employees who give their best every day to the pursuit of important new medicines through scientific discoveries."

Details of the rankings and survey results will be published online on Sept. 16 at www.sciencecareers.org/TopEmployers2011 and will be included in the Oct. 7 print issue of Science.

Regeneron, founded in 1988, currently has approximately 1,670 employees, of whom more than 300 hold Ph.D. or M.D. degrees.  Regeneron has added about 1,000 employees since 2007, primarily to support its research and development programs.  The Company proprietary VelociGene® and VelocImmune® technologies were used to discover and develop eight fully-human monoclonal antibodies that are in clinical development.  The Company's Trap fusion protein technology was applied to develop ARCALYST® (rilonacept) and two product candidates that have completed Phase 3 clinical studies.

About the Top Employers SurveyThe Science and Science Careers' annual Top Employers Survey polls employees in the
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Regeneron Announces Clinical Presentations at ASRS 2011 Annual Meeting
2. Regeneron Reports Second Quarter 2011 Financial and Operating Results
3. Sanofi and Regeneron Report Positive Phase 2b Trial Results with Sarilumab in Rheumatoid Arthritis
4. Trading in Regeneron Common Stock Halted
5. Regeneron Reports First Quarter 2011 Financial and Operating Results
6. Regeneron Announces Presentation at the Bank of America Merrill Lynch 2011 Health Care Conference
7. Regeneron and Bayer Report Positive Results for VEGF Trap-Eye in Second Phase 3 Study in Central Retinal Vein Occlusion
8. Regeneron and Bayer Announce Start of Phase 3 Clinical Program in Diabetic Macular Edema
9. Regeneron Announces Presentation at the 10th Annual Needham Healthcare Conference
10. Sanofi-aventis and Regeneron Report Top-line Results from Phase III Study with aflibercept (VEGF Trap) in Second-Line Non-Small Cell Lung Cancer
11. Regeneron Announces March 2011 Investor Conference Presentations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2015)... BioPharma, Inc. (PDL) (NASDAQ: PDLI ) today reported ... Total revenues for the first quarter ... $136.8 million in the first quarter of 2014. Revenues ... million in royalty and license payments from PDL,s licensees ... net royalty payments from acquired royalty rights and a ...
(Date:5/6/2015)... Inc. (NYSE: LCI ) today reported financial results ... 2015.  For the fiscal 2015 third ... $80.0 million in last year,s third quarter.  Gross profit ... sales, from $56.1 million, or 70% of net sales.  ... from $10.6 million for the fiscal 2014 third quarter.  ...
(Date:5/6/2015)... May 6, 2015 The Parenteral Drug Association ... finalized agreement with Richard M. Johnson to ... "We are very pleased to have Richard Johnson ... Hal Baseman , the Chair of the Board of ... and growth.  Richard has led a strong staff and ...
Breaking Medicine Technology:PDL BioPharma Announces First Quarter 2015 Financial Results 2PDL BioPharma Announces First Quarter 2015 Financial Results 3PDL BioPharma Announces First Quarter 2015 Financial Results 4PDL BioPharma Announces First Quarter 2015 Financial Results 5PDL BioPharma Announces First Quarter 2015 Financial Results 6PDL BioPharma Announces First Quarter 2015 Financial Results 7Lannett Reports Strong Fiscal 2015 Third-quarter Financial Results 2Lannett Reports Strong Fiscal 2015 Third-quarter Financial Results 3Lannett Reports Strong Fiscal 2015 Third-quarter Financial Results 4Lannett Reports Strong Fiscal 2015 Third-quarter Financial Results 5Lannett Reports Strong Fiscal 2015 Third-quarter Financial Results 6Lannett Reports Strong Fiscal 2015 Third-quarter Financial Results 7Lannett Reports Strong Fiscal 2015 Third-quarter Financial Results 8PDA Extends Richard M. Johnson as President/CEO for Six Additional Years 2
... Indicate Bioequivalent Pharmacokinetics With Reduced Risk,of ... April 25, 2007 /PRNewswire-FirstCall/ -- ADVENTRX,Pharmaceuticals, ... company focused on commercializing proprietary product,candidates ... infectious diseases,today announced positive results from ...
... 2007 - Basilea Pharmaceutica Ltd.,(SWX:BSLN) reported today ... severe chronic hand eczema can benefit from,re-treatment ... alitretinoin was found to be effective in ... to topical treatments.,This pivotal trial demonstrated that ...
Cached Medicine Technology:ADVENTRX Announces Positive Data From Preclinical Pharmacokinetic,Testing of ANX-514 (Docetaxel Emulsion) 2ADVENTRX Announces Positive Data From Preclinical Pharmacokinetic,Testing of ANX-514 (Docetaxel Emulsion) 3ADVENTRX Announces Positive Data From Preclinical Pharmacokinetic,Testing of ANX-514 (Docetaxel Emulsion) 4ADVENTRX Announces Positive Data From Preclinical Pharmacokinetic,Testing of ANX-514 (Docetaxel Emulsion) 5Basilea Reports Positive Re-treatment Results from a Second Phase,III Trial of Alitretinoin for Patients with Severe Chronic Hand,Eczema 2Basilea Reports Positive Re-treatment Results from a Second Phase,III Trial of Alitretinoin for Patients with Severe Chronic Hand,Eczema 3Basilea Reports Positive Re-treatment Results from a Second Phase,III Trial of Alitretinoin for Patients with Severe Chronic Hand,Eczema 4Basilea Reports Positive Re-treatment Results from a Second Phase,III Trial of Alitretinoin for Patients with Severe Chronic Hand,Eczema 5
(Date:5/6/2015)... 06, 2015 A quality built chicken coop condo ... yet practical way to raise chickens on a pasture. By ... Condo, it will have a chicken tractor that stands up to ... many years, as it is able to flex to uneven ground ... of the land are fertilized, and it will help provide the ...
(Date:5/6/2015)... The Canton Group is joining Lardarius ... 6th annual charity softball game. The event takes place on ... Stadium. Past years guests include Joe Flacco, John Harbaugh, Ed ... on sale if you are interested in attending. , ... such as SOAR Baltimore and The CollegeBound ...
(Date:5/6/2015)... Animals make just as good friends as they do pets. ... An Ohio veterinarian has been observing this for ... advantages of owning a pet. , “When animals and humans ... there are proven health benefits for people-- including physical, mental ... Animal Medical Center of Streetsboro said. Every May, ...
(Date:5/6/2015)... Anitha Nallari, MD has joined ... Inc. in Columbus, OH. Dr. Nallari will see patients ... in breast cancer, lung cancer, GI and gallbladder cancer, head ... benign hematology. , Dr. Anitha Nallari is Board ... American Board of Internal Medicine. She completed her medical education ...
(Date:5/6/2015)... Anitoa Systems, (“Anitoa”), a Palo Alto startup established ... has successfully demonstrated a handheld real time quantitative-polymerase-chain-reaction system ... handheld qPCR is shown to be capable of detecting ... B, C, and E. Coli. This qPCR system has ... over 9 orders of magnitude dynamic range. A ...
Breaking Medicine News(10 mins):Health News:Chicken Coop Condo Launches the Chicken Tractor 2Health News:The Canton Group Sponsors Ravens Charity Softball Event 2Health News:The Canton Group Sponsors Ravens Charity Softball Event 3Health News:Veterinarian Supports 2015 HABRI Study Citing Increase in Health Advantages of Pet Owners 2Health News:Veterinarian Supports 2015 HABRI Study Citing Increase in Health Advantages of Pet Owners 3Health News:New Oncologist to Join Hematology Oncology Consultants, Inc. 2Health News:New Oncologist to Join Hematology Oncology Consultants, Inc. 3Health News:Anitoa Systems Demonstrates Compact qPCR using Ultra Low-Light CMOS Bio-Optical Sensor 2Health News:Anitoa Systems Demonstrates Compact qPCR using Ultra Low-Light CMOS Bio-Optical Sensor 3
... test, researcher says, , THURSDAY, Dec. 3 (HealthDay News) -- ... between vitamin D and heart disease. , People with high ... D activation in the body were found to be twice ... heart failure, the study found. , The finding may lead ...
... LONDON, Dec. 3 Chiltern International Limited (Chiltern), a global ... in Europe, the Americas and Asia, today announces the appointment ... Global Quality & Medical Affairs. Dr. Moore is based at ... physician with 15 years of industry experience. Prior to joining ...
... , PASADENA, Calif., Dec. 3 For California,s 3.4 ... one of the most significant threats to not only their ... , "As the recession and market declines have taken their ... shore up their financial safety net with enhanced disability coverage," ...
... , Research could lead ... prevent mutations known to result in cancer and genetic diseases ... for the first time observed the movement of a single ... one. More significantly, they have identified a previously unknown step ...
... ... test – HiFi DNA Tech sues FDA on December 11 for blocking new technology. ... Trumbull, CN (PRWEB) December 2, ... invasive cancer workup procedure, also known as colposcopic biopsy, is harmful and may be ...
... , , NEW YORK, ... human H1N1/09 Type A influenza ("Swine Flu") has reached a ... with at least 6,500 fatalities. Since there is no ... numbers undoubtedly understate the real situation. , ...
Cached Medicine News:Health News:Vitamin D May Be Tied to Heart Disease Via Genes 2Health News:Chiltern Names Dr. Sharon Moore as Executive VP, Global Quality & Medical Affairs 2Health News:New Disability Income Insurance Options Provide More Choice for California's Small Business Owners 2Health News:New Disability Income Insurance Options Provide More Choice for California's Small Business Owners 3Health News:New Disability Income Insurance Options Provide More Choice for California's Small Business Owners 4Health News:Wayne State Researchers Report a Possible 'Proofreading' Step in DNA Synthesis by Observing Single Molecules of DNA Polymerase 2Health News:Wayne State Researchers Report a Possible 'Proofreading' Step in DNA Synthesis by Observing Single Molecules of DNA Polymerase 3Health News:Harmful Procedures on Young Women Caused by Outdated HPV test, not by Pap Test 2Health News:Buchang Global Health Forum 2009: An Innovative Approach for Management of H1N1 Swine Flu 2
Liquichek Hematology Control (C) is an assayed hematology control for evaluating the performance of Coulter hematology instruments with complete CBC and VCS 5-part differential technology....
Each Liquichek™ Antigen Panel is a set of samples from various donors with various levels of antigen. The panel is intended to depict a range of clinical states for individuals in the early sta...
Liquichek Unassayed Chemistry Control (Human) is a comprehensive, stable, liquid product designed to monitor general and special chemistry tests....
Liquichek Autoimmune Controls are individual controls for monitoring the performance of autoimmune assays....
Medicine Products: